A novel therapy combines antibiotics rifaximin and clarithromycin to treat Mycobacterium abscessus, a non-tuberculous mycobacterium that causes chronic lung-related infections.
New Therapy Counters Antibiotic-Resistant Mycobacterium Abscessus Infections miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Massachusetts Institute of Technology The discovery can help to cure bacterial infections without inducing resistance or causing harm to good bacteria. SMART AMR researchers Boon Chong Goh (left) and Linh Chi Dam evaluate bacterial cells after treatment with lysins. Photo courtesy of SMART.
Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have developed a method to produce customizable engineered lysins that can be used to selectively kill bacteria of interest while leaving others unharmed. The discovery presents a promising alternative to antibiotics for treating existing drug-resistant bacteria and bacterial infections without the risk of causing resistance.